- Home
- INKT vs BTMD Comparison
INKT vs BTMD Comparison
Compare INKT & BTMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INKT | BTMD |
|---|---|---|
| Founded | 2017 | 2012 |
| Country | United States | United States |
| Employees | N/A | 217 |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.6M | 65.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | INKT | BTMD |
|---|---|---|
| Price | $11.04 | $2.13 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $35.00 | $6.00 |
| AVG Volume (30 Days) | 10.1K | ★ 156.3K |
| Earning Date | 03-17-2026 | 03-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 270.48 |
| EPS | N/A | ★ 0.78 |
| Revenue | N/A | ★ $195,645,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.37 |
| P/E Ratio | ★ N/A | $2.73 |
| Revenue Growth | N/A | ★ 1.34 |
| 52 Week Low | $6.34 | $2.02 |
| 52 Week High | $76.00 | $5.00 |
Technical Indicators
Market Signals| Indicator | INKT | BTMD |
|---|---|---|
| Relative Strength Index (RSI) | 39.47 | 38.95 |
| Support Level | $10.98 | $2.02 |
| Resistance Level | $11.48 | $2.24 |
| Average True Range (ATR) | 0.41 | 0.13 |
| MACD | -0.09 | 0.01 |
| Stochastic Oscillator | 10.93 | 18.99 |
Price Performance
Historical ComparisonAbout INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
About BTMD Biote Corp.
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The company derives revenue from United States and also has its presence in other countries.